“We are encouraged by growth in the fourth quarter of 2025, driven in particular by the momentum of our critical care franchise with ZYNRELEF and APONVIE,” said Craig Collard, CEO. “In addition to our revenue growth, we are very pleased with the continued progress made in all aspects of our business over the past year.” Preliminary Q4 and FY25 Updates: Net income of approximately $40.5 million for the three months ended December 31. ZYNRELEF net income of approximately $12.5 million for the three months ended December 31. APONVIE net income of approximately $3.8 million for the three months ended December 31. CINVANTI net income of approximately $22.9 million for the three months ended December 31. SUSTOL net income of approximately $1.3 million for the three months ended December 31. Net revenue of approximately $154.9 million for FY25. ZYNRELEF achieved the largest quarter-over-quarter revenue growth within the portfolio in Q4.
First published in the fly – the definitive source of breaking financial news that moves the market in real time. Try it now >>
See the most popular stocks from insiders on TipRanks >>
Read more about HRTX:
Disclaimer and disclosure Report a problem